Oxidative, multistep activation of the noncanonical NF-κB pathway via disulfide Bcl-3/p50 complex

被引:25
作者
Cristofanon, Silvia [1 ,2 ]
Morceau, Franck [2 ]
Scovassi, A. Ivana [3 ]
Dicato, Mario [2 ]
Ghibelli, Lina [1 ]
Diederich, Marc [2 ]
机构
[1] Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy
[2] Hop Kirchberg, Lab Biol Mol & Ecllulaire Canc, Fdn Rech Canc & Maladies Sang, L-2540 Luxembourg, Luxembourg
[3] Ist Genet Mol Consiglio Nazl Ric, Pavia, Italy
关键词
glutathione; Bcl-2; ROS; p38; GLUTATHIONE DEPLETION; MAP KINASE; NUCLEAR TRANSLOCATION; BCL-2; EXPRESSION; P50; HOMODIMERS; CELLS; APOPTOSIS; TRANSCRIPTION; BINDING; MODULATION;
D O I
10.1096/fj.07-104109
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Buthionine sulfoximine ( BSO) is a well-known inhibitor of glutathione synthesis, producing slow glutathione ( GSH) depletion and oxidative stress; some "responder" cells avoid BSO-induced death by trans-activating the prosurvival protein Bcl-2. Here we show that BSO activates a noncanonical, inhibitory NF-kappa B- and p65-independent NF-kappa B pathway via a multistep process leading to the up-regulation of Bcl-2. The slow BSO-induced GSH depletion allows separation of two redox-related phases, namely, early thiol disequilibrium and late frank oxidative stress; each phase contributes to the progressive activation of a p50-p50 homodimer. The early phase, coinciding with substantial thiol depletion, produces a cytosolic preparative complex, consisting of p50 and its interactor Bcl-3 linked by interprotein disulfide bridges. The late phase, coinciding with reactive oxygen species production, is responsible, probably via p38 activation, for nuclear targeting of the complex and trans-activation of Bcl-2. Cristofanon, S., Morceau, F., Scovassi, A. I., Dicato, M., Ghibelli, L., Diederich, M. Oxidative, multistep activation of the noncanonical NF-kappa B pathway via disulfide Bcl-3/p50 complex. FASEB J. 23, 45-57 ( 2009)
引用
收藏
页码:45 / 57
页数:13
相关论文
共 43 条
[11]   Expression of glutathione S-transferase P1-1 in leukemic cells is regulated by inducible AP-1 binding [J].
Duvoix, A ;
Schnekenburger, M ;
Delhalle, S ;
Blasius, R ;
Borde-Chiché, P ;
Morceau, F ;
Dicato, M ;
Diederich, M .
CANCER LETTERS, 2004, 216 (02) :207-219
[12]   The transcription factor nuclear factor-kappa B and cancer [J].
Escarcega, R. O. ;
Fuentes-Alexandro, S. ;
Garcia-Carrasco, M. ;
Gatica, A. ;
Zamora, A. .
CLINICAL ONCOLOGY, 2007, 19 (02) :154-161
[13]   Human proliferating cell nuclear antigen, poly(ADP-ribose) polymerase-1, and p21waf1/cip1 -: A dynamic exchange of partners [J].
Frouin, I ;
Maga, G ;
Denegri, M ;
Riva, F ;
Savio, M ;
Spadari, S ;
Prosperi, E ;
Scovassi, AI .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (41) :39265-39268
[14]   THE CANDIDATE PROTOONCOGENE BCL-3 ENCODES A TRANSCRIPTIONAL COACTIVATOR THAT ACTIVATES THROUGH NF-KAPPA-B P50 HOMODIMERS [J].
FUJITA, T ;
NOLAN, GP ;
LIOU, HC ;
SCOTT, ML ;
BALTIMORE, D .
GENES & DEVELOPMENT, 1993, 7 (7B) :1354-1363
[15]   Glutathione depletion causes cytochrome c release even in the absence of cell commitment to apoptosis [J].
Ghibelli, L ;
Coppola, S ;
Fanelli, C ;
Rotilio, G ;
Civitareale, P ;
Scovassi, AI ;
Ciriolo, MR .
FASEB JOURNAL, 1999, 13 (14) :2031-2036
[16]   Rescue of cells from apoptosis by inhibition of active GSH extrusion [J].
Ghibelli, L ;
Fanelli, C ;
Rotilio, G ;
Lafavia, E ;
Coppola, S ;
Colussi, C ;
Civitareale, P ;
Ciriolo, MR .
FASEB JOURNAL, 1998, 12 (06) :479-486
[17]   STRUCTURE OF NF-KAPPA-B P50 HOMODIMER BOUND TO A KAPPA-B SITE [J].
GHOSH, G ;
VANDUYNE, G ;
GHOSH, S ;
SIGLER, PB .
NATURE, 1995, 373 (6512) :303-310
[18]   Introduction to NF-κB:: players, pathways, perspectives [J].
Gilmore, T. D. .
ONCOGENE, 2006, 25 (51) :6680-6684
[19]   NF-KAPPA-B SUBUNIT REGULATION IN NONTRANSFORMED CD4+ LYMPHOCYTES-T [J].
KANG, SM ;
TRAN, AC ;
GRILLI, M ;
LENARDO, MJ .
SCIENCE, 1992, 256 (5062) :1452-1456
[20]   Deregulated NF-κB activity in haematological malignancies [J].
Keutgens, Aurore ;
Robert, Isabelle ;
Viatour, Patrick ;
Chariot, Alain .
BIOCHEMICAL PHARMACOLOGY, 2006, 72 (09) :1069-1080